首页> 外文期刊>Melanoma research >Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status
【24h】

Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status

机译:原发性皮肤黑素瘤中趋化因子受体CXCR4 mRNA与已确定的组织病理学预后和BRAF状态的相关性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Dysregulation of the chemokine receptor CXCR4 is relevant in melanoma progression, and the CXCR4/CXCL12 axis has been shown to activate cell cycle progression and malignant cell migration through stimulation of the mitogen-activated protein kinase pathway. Studies ascertaining the potential utility of CXCR4 mRNA as a prognosticator in melanoma have focused mainly on metastatic melanoma with conflicting results. In the light of this, we sought to explore the potential relationship between CXCR4 mRNA expression with established histopathologic prognosticators and BRAF status in melanoma. Archived consecutive samples (n=107) of primary cutaneous melanoma were retrieved and assessed for the following: CXCR4 mRNA (semiquantitative RT-PCR) and BRAF exon 15 status (DNA Sanger sequencing). Statistical analyses included correlation between CXCR4 mRNA levels and established histopathologic prognosticators as well as the BRAF status using univariate and multiple linear methods. Multivariable analyses revealed a significant correlation between elevated CXCR4 mRNA (low C-t value) and the presence of BRAF mutation (P=0.02). Absence of a brisk host response was associated with elevated CXCR4 mRNA expression (P=0.04). CXCR4 mRNA was significantly lower in AJCC stage 2 compared with stage 1 after controlling for significant clinical prognosticators (P=0.02). The association between elevated CXCR4 mRNA and absence of a brisk host response suggests that CXCR4 may be involved in regulation of the host immune response in melanoma and is a molecule of potential utility as a biomarker for recruiting melanoma patients for immunotherapy. Higher CXCR4 mRNA in patients with a BRAF mutation suggests its utility as a putative therapeutic target.
机译:趋化因子受体CXCR4的失调与黑色素瘤的进展有关,并且已证明CXCR4 / CXCL12轴通过刺激丝裂原激活的蛋白激酶途径来激活细胞周期进程和恶性细胞迁移。确定CXCR4 mRNA在黑色素瘤中作为预后因子的潜在用途的研究主要集中在转移性黑色素瘤上,其结果相互矛盾。有鉴于此,我们试图探讨CXCR4 mRNA表达与既定的组织病理学预后因素之间的潜在关系以及黑色素瘤的BRAF状态。检索存档的连续样本(n = 107)原发性皮肤黑色素瘤并进行以下评估:CXCR4 mRNA(半定量RT-PCR)和BRAF外显子15状态(DNA Sanger测序)。统计分析包括CXCR4 mRNA水平与确定的组织病理学预后因素之间的相关性,以及使用单变量和多种线性方法得出的BRAF状态。多变量分析显示,升高的CXCR4 mRNA(低C-t值)与BRAF突变的存在之间存在显着相关性(P = 0.02)。缺乏轻快的宿主反应与CXCR4 mRNA表达升高有关(P = 0.04)。在控制了重要的临床预后后,AJCC 2期患者的CXCR4 mRNA水平明显低于1期患者(P = 0.02)。 CXCR4 mRNA升高与缺乏轻快的宿主反应之间的关联表明,CXCR4可能参与黑色素瘤宿主免疫反应的调节,并且是潜在的分子,可作为招募黑色素瘤患者进行免疫治疗的生物标记。具有BRAF突变的患者中较高的CXCR4 mRNA提示其可作为推定的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号